GlobeNewswire Inc.··Not SpecifiedEvaxion's Personalized Cancer Vaccine Shows 75% Response Rate in Extended Trial
Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.
MRKEVAXphase 2 trialimmunotherapy